{"brief_title": "An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)", "brief_summary": "Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250 patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for up to 48 weeks.", "condition": ["Lung Disease", "Pulmonary Fibrosis"], "intervention_type": ["Drug"], "intervention_name": ["interferon-gamma 1b"], "description": ["200 mcg, SQ, 3x per week"], "criteria": "Male or Female Idiopathic Pulmonary Fibrosis 20-79 years Must have participated in the InterMune protocol GIPF-001 study.", "gender": "All", "minimum_age": "20 Years", "maximum_age": "79 Years", "healthy_volunteers": "No", "keyword": "IPF", "mesh_term": ["Fibrosis", "Lung Diseases", "Pulmonary Fibrosis", "Idiopathic Pulmonary Fibrosis", "Idiopathic Interstitial Pneumonias", "Interferons", "Interferon-gamma"], "id": "NCT00052052"}